Ardent Health to Release Q4 and Full Year 2025 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy ARDT?
Source: Newsfilter
- Earnings Release Schedule: Ardent Health will issue its Q4 and full year 2025 financial results after market close on March 4, 2026, reflecting the company's ongoing growth and development in healthcare services.
- Conference Call Timing: A conference call will be held on March 5, 2026, at 10 a.m. ET to review the financial results and conduct a Q&A session, aimed at enhancing investor understanding and confidence in the company's performance.
- Webcast Information: Investors can listen to the live broadcast of the conference call via the Investor Relations section of Ardent Health's website, ensuring to register and install necessary audio software at least 15 minutes prior to the start time for smooth participation.
- Company Overview: Ardent Health provides healthcare services in mid-sized urban communities across the U.S., operating 30 acute care hospitals and 280 sites of care, committed to improving healthcare accessibility through innovative services and technologies, showcasing its leadership in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARDT
Wall Street analysts forecast ARDT stock price to rise
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 9.480
Low
10.00
Averages
13.73
High
17.00
Current: 9.480
Low
10.00
Averages
13.73
High
17.00
About ARDT
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ardent Health Securities Class Action Notice
- Class Action Deadline: Purchasers of Ardent Health, Inc. (NYSE: ARDT) securities are reminded that the deadline to apply as lead plaintiff is March 9, 2026, for those who bought shares between July 18, 2024, and November 12, 2025, potentially entitled to compensation without out-of-pocket costs.
- Lawsuit Allegations: The lawsuit claims that Ardent Health made false representations regarding its accounts receivable, asserting that it utilized 'detailed reviews of historical collections' for collectability assessments, which misled investors and resulted in losses when the truth emerged.
- Insufficient Liability Insurance: Ardent Health reportedly did not maintain adequate professional malpractice liability insurance to cover claims arising from its operations, particularly in the New Mexico market, where social inflationary pressures in medical malpractice cases have been increasing, heightening investor risk.
- Counsel Selection Advice: Investors are encouraged to select qualified legal counsel with a proven track record, as the Rosen Law Firm is recommended for its success in securities class actions, having recovered over $438 million for investors in 2019 alone.
See More
Ardent Health Class Action Lawsuit Announcement
- Lawsuit Timeline: The class action lawsuit against Ardent Health targets securities purchasers from July 18, 2024, to November 12, 2025, with a deadline of March 9, 2026, for investors to apply as lead plaintiffs to represent others in the lawsuit.
- Financial Misrepresentation Allegations: The lawsuit alleges that Ardent Health and its executives failed to disclose the true state of accounts receivable during the class period, resulting in materially misleading financial reports that impacted investor decisions.
- Significant Revenue Decline: On November 12, 2025, Ardent Health revealed a $43 million decrease in third-quarter revenue, primarily due to adjustments from a new revenue accounting system and reevaluated historical collection trends, leading to a nearly 34% drop in stock price.
- Increased Liability Reserves: The lawsuit also highlights a $54 million increase in professional liability reserves due to medical malpractice claims in New Mexico, reflecting significant social inflation pressures and exacerbating investor concerns about the company's financial stability.
See More
Ardent Health Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ardent Health and certain officers, seeking damages for investors who purchased Ardent securities between July 18, 2024, and November 12, 2025.
- Financial Misrepresentation Allegations: The complaint alleges that Ardent Health overstated its third-quarter 2025 revenue due to inadequate assessments of accounts receivable collectability following a transition to a new revenue accounting system, raising concerns about the company's financial transparency.
- EBITDA Guidance Downgrade: The lawsuit claims that Ardent's 2025 EBITDA guidance will be reduced by $57.5 million, approximately 9.6%, due to persistent industry-wide cost pressures, indicating significant financial challenges that could undermine investor confidence moving forward.
- Investor Action Recommendations: Affected investors must request to be appointed as lead plaintiffs by March 9, 2026, to participate in potential recoveries, with the law firm operating on a contingency fee basis, thereby minimizing financial risks for investors.
See More
Faruqi & Faruqi Investigates Ardent Health for Securities Violations
- Investor Loss Alert: Faruq & Faruqi LLP is urging investors who suffered losses exceeding $100,000 in Ardent Health between July 18, 2024, and November 12, 2025, to contact partner Josh Wilson, indicating potential severe legal liabilities for the company.
- Financial Reporting Errors: Ardent disclosed a $43 million revenue reduction and a $54 million increase in professional liability reserves in its Q3 2025 financial report, leading to a 33.81% drop in stock price to $9.30 per share on November 13, 2025, reflecting market concerns over its financial health.
- Class Action Progress: Faruq & Faruqi is investigating potential claims against Ardent and reminds investors to apply to be lead plaintiffs in the federal securities class action by March 9, 2026, indicating the case could significantly impact many investors' rights.
- Legal Consultation Opportunity: The firm encourages anyone with information regarding Ardent's conduct, including whistleblowers and former employees, to reach out, highlighting the complexity and potential widespread implications of the case.
See More
Ardent Health Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Ardent Health and its executives, alleging securities fraud that led to a significant stock drop due to potential violations of federal securities laws.
- Stock Price Plunge: Following the announcement of a $43 million revenue decrease on November 12, 2025, Ardent Health's stock plummeted from $14.05 to $9.30 per share, a decline of over 33%, which directly undermined investor confidence.
- Financial Transparency Issues: The lawsuit claims that Ardent Health did not primarily rely on “detailed reviews of historical collections” for assessing the collectability of accounts receivable, but instead used a 180-day cliff, resulting in distorted financial statements.
- Legal Implications: Investors are encouraged to apply to lead the case by March 9, 2026, and if successful, the lawsuit could have significant repercussions on Ardent Health's financial health and further impact its market reputation.
See More
Ardent Health Investors Alerted on Class Action Lawsuit
- Lawsuit Notification: Kahn Swick & Foti reminds investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, to file lead plaintiff applications by March 9, 2026, to participate in the ongoing class action lawsuit against the company.
- Financial Disclosure Issues: On November 12, 2025, Ardent disclosed a $43 million revenue drop for Q3 2025, primarily due to a transition to a new revenue accounting system and evaluations of historical collection trends, leading to a nearly 34% drop in share price the following day.
- EBITDA Guidance Cut: The company revised its 2025 EBITDA guidance down to $530 million to $555 million, a reduction of approximately 9.6% from the previous range of $575 million to $625 million, reflecting persistent industry-wide cost pressures and payer denials.
- Increased Legal Liabilities: Ardent recorded a $54 million increase in professional liability reserves related to settlements and ongoing litigation from 2019 to 2022 in New Mexico, indicating significant challenges in legal compliance and potential future liabilities.
See More
Ardent Health Securities Class Action Notice
- Class Action Deadline: Purchasers of Ardent Health, Inc. (NYSE: ARDT) securities are reminded that the deadline to apply as lead plaintiff is March 9, 2026, for those who bought shares between July 18, 2024, and November 12, 2025, potentially entitled to compensation without out-of-pocket costs.
- Lawsuit Allegations: The lawsuit claims that Ardent Health made false representations regarding its accounts receivable, asserting that it utilized 'detailed reviews of historical collections' for collectability assessments, which misled investors and resulted in losses when the truth emerged.
- Insufficient Liability Insurance: Ardent Health reportedly did not maintain adequate professional malpractice liability insurance to cover claims arising from its operations, particularly in the New Mexico market, where social inflationary pressures in medical malpractice cases have been increasing, heightening investor risk.
- Counsel Selection Advice: Investors are encouraged to select qualified legal counsel with a proven track record, as the Rosen Law Firm is recommended for its success in securities class actions, having recovered over $438 million for investors in 2019 alone.
See More
Ardent Health Class Action Lawsuit Announcement
- Lawsuit Timeline: The class action lawsuit against Ardent Health targets securities purchasers from July 18, 2024, to November 12, 2025, with a deadline of March 9, 2026, for investors to apply as lead plaintiffs to represent others in the lawsuit.
- Financial Misrepresentation Allegations: The lawsuit alleges that Ardent Health and its executives failed to disclose the true state of accounts receivable during the class period, resulting in materially misleading financial reports that impacted investor decisions.
- Significant Revenue Decline: On November 12, 2025, Ardent Health revealed a $43 million decrease in third-quarter revenue, primarily due to adjustments from a new revenue accounting system and reevaluated historical collection trends, leading to a nearly 34% drop in stock price.
- Increased Liability Reserves: The lawsuit also highlights a $54 million increase in professional liability reserves due to medical malpractice claims in New Mexico, reflecting significant social inflation pressures and exacerbating investor concerns about the company's financial stability.
See More
Ardent Health Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ardent Health and certain officers, seeking damages for investors who purchased Ardent securities between July 18, 2024, and November 12, 2025.
- Financial Misrepresentation Allegations: The complaint alleges that Ardent Health overstated its third-quarter 2025 revenue due to inadequate assessments of accounts receivable collectability following a transition to a new revenue accounting system, raising concerns about the company's financial transparency.
- EBITDA Guidance Downgrade: The lawsuit claims that Ardent's 2025 EBITDA guidance will be reduced by $57.5 million, approximately 9.6%, due to persistent industry-wide cost pressures, indicating significant financial challenges that could undermine investor confidence moving forward.
- Investor Action Recommendations: Affected investors must request to be appointed as lead plaintiffs by March 9, 2026, to participate in potential recoveries, with the law firm operating on a contingency fee basis, thereby minimizing financial risks for investors.
See More
Faruqi & Faruqi Investigates Ardent Health for Securities Violations
- Investor Loss Alert: Faruq & Faruqi LLP is urging investors who suffered losses exceeding $100,000 in Ardent Health between July 18, 2024, and November 12, 2025, to contact partner Josh Wilson, indicating potential severe legal liabilities for the company.
- Financial Reporting Errors: Ardent disclosed a $43 million revenue reduction and a $54 million increase in professional liability reserves in its Q3 2025 financial report, leading to a 33.81% drop in stock price to $9.30 per share on November 13, 2025, reflecting market concerns over its financial health.
- Class Action Progress: Faruq & Faruqi is investigating potential claims against Ardent and reminds investors to apply to be lead plaintiffs in the federal securities class action by March 9, 2026, indicating the case could significantly impact many investors' rights.
- Legal Consultation Opportunity: The firm encourages anyone with information regarding Ardent's conduct, including whistleblowers and former employees, to reach out, highlighting the complexity and potential widespread implications of the case.
See More
Ardent Health Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Ardent Health and its executives, alleging securities fraud that led to a significant stock drop due to potential violations of federal securities laws.
- Stock Price Plunge: Following the announcement of a $43 million revenue decrease on November 12, 2025, Ardent Health's stock plummeted from $14.05 to $9.30 per share, a decline of over 33%, which directly undermined investor confidence.
- Financial Transparency Issues: The lawsuit claims that Ardent Health did not primarily rely on “detailed reviews of historical collections” for assessing the collectability of accounts receivable, but instead used a 180-day cliff, resulting in distorted financial statements.
- Legal Implications: Investors are encouraged to apply to lead the case by March 9, 2026, and if successful, the lawsuit could have significant repercussions on Ardent Health's financial health and further impact its market reputation.
See More
Ardent Health Investors Alerted on Class Action Lawsuit
- Lawsuit Notification: Kahn Swick & Foti reminds investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, to file lead plaintiff applications by March 9, 2026, to participate in the ongoing class action lawsuit against the company.
- Financial Disclosure Issues: On November 12, 2025, Ardent disclosed a $43 million revenue drop for Q3 2025, primarily due to a transition to a new revenue accounting system and evaluations of historical collection trends, leading to a nearly 34% drop in share price the following day.
- EBITDA Guidance Cut: The company revised its 2025 EBITDA guidance down to $530 million to $555 million, a reduction of approximately 9.6% from the previous range of $575 million to $625 million, reflecting persistent industry-wide cost pressures and payer denials.
- Increased Legal Liabilities: Ardent recorded a $54 million increase in professional liability reserves related to settlements and ongoing litigation from 2019 to 2022 in New Mexico, indicating significant challenges in legal compliance and potential future liabilities.
See More
